Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PLUR, unsubscribe in one click. Privacy
PLUR holds $8.9M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.5M/quarter from operations, an estimated runway of 5.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
Our recurring operating losses and negative cash flow raise substantial doubt about our ability to continue as a going concern.10-K, Sep 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PLUR files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLUR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →